TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03252496
Drug: 250 mL Crystalloid over 5 minutes
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer acetate 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
Study: NCT03252496
Drug: 500 mL Crystalloid over 55 minutes
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer acetate 500 mL will be administered over 55 minutes following colloid or crystalloid administration
Study: NCT03252496
Drug: 250 mL Colloid over 60 minutes
Normalized name: Colloidal silica
DrugBank: Silicon dioxide (DB11132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After 60 minutes of intrathecal injection, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 60 minutes
Study: NCT03252496
Drug: Intravenous Ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
Study: NCT00454181
Drug: Interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 IU interferon-alpha lozenges taken 3 times per day for 24 weeks
Study: NCT02195791
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone 30mg/tab (oral) 1 tab once daily for 7 days
Study: NCT01293032
Drug: Systemic Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo chemotherapy
Study: NCT01293032
Drug: Tamoxifen Citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Undergo hormonal therapy
Study: NCT00436969
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celestone (betamethasone sodium phosphate and acetate) - 2 mL
Study: NCT00321984
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 30 mg, capsules, orally, once daily for 4 weeks.
Study: NCT00321984
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
Study: NCT01847664
Drug: Rifamycin SV-MMX® 400 mg b.i.d.
DrugBank: Rifamycin (DB11753)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01847664
Drug: Rifamycin SV-MMX® 600 mg t.i.d.
DrugBank: Rifamycin (DB11753)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01847664
Drug: Rifamycin SV-MMX® Placebo
DrugBank: Rifamycin (DB11753)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01750398
Drug: Testosterone cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
Study: NCT01750398
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin is a hormone therapy, for intramuscular injectionis. It is classified as an LHRH agonist.
Study: NCT01750398
Drug: Leuprolide
Normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist. For intramuscular injection.
Study: NCT01125176
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg oral dosing every other day
Study: NCT01125176
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: varying oral doses every other day (max 25 mg/day)
Study: NCT03792776
Drug: cuff inflation with lidocaine 2%
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endotracheal tube cuff inflation with lidocaine 2%
Study: NCT00006460
Drug: hyperbaric oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00658372
Drug: PD 0332334
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
Study: NCT00658372
Drug: PD 0332334
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsules, oral, 300 mg BID, 8 weeks with 2 week taper
Study: NCT00658372
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules, oral, Paroxetine, 20 mg QD, 8 weeks with 2 week taper
Study: NCT02203331
Drug: Levonorgestrel
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
Study: NCT02203331
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received Anastrozole 300 µg/d or 600 µg/d or 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
Study: NCT02777073
Drug: Victoza
Normalized name: Victoza
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose of Liraglutide
Study: NCT02777073
Drug: Dapagliflozin 10mg Tab
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: single dose of 10 mg dapagliflozin
Study: NCT01197144
Drug: adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous, 40 mg every other week for 4 weeks
Study: NCT00740779
Drug: Silodosin 8 mg
Normalized name: silodosin 8 MG
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Silodosin 8 mg daily
Study: NCT00740779
Drug: Silodosin 4 mg
Normalized name: silodosin 4 MG
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Silodosin 4 mg daily
Study: NCT00450203
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
Study: NCT00450203
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
Study: NCT00450203
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1250mg/day Day 1-21 of each cycle of chemotherapy (6 cycles) plus day 1-21 of each maintenance course every 21 days for 6 doses.
Study: NCT02344069
Drug: Fibrinogen
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human fibrinogen concentrate as a injection
Study: NCT01231633
Drug: Ozurdex
Normalized name: Ozurdex
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ozurdex, 0.7mg dexamethasone
Study: NCT01231633
Drug: Avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.
Study: NCT05029596
Drug: Normal Saline Group
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 10cc NS flush will be administered intravenously through the peripherally inserted central line catheter after administration of medication, blood products, and blood draws. In addition the peripherally inserted central line catheter will be flushed intravenously with 10cc Normal Saline every 24 hours.
Study: NCT00875017
Drug: Lanthanum Carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 x 1000mg tablet
Study: NCT00875017
Drug: Sevelamer
Normalized name: Sevelamer
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 x 800mg tablets
Study: NCT02689219
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both cohorts will be treated similarly and in parallel but analyzed separately.
Study: NCT02674581
Drug: Oral BMS-663068 (pro-drug)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral BMS-663068 (pro-drug), metabolized to active BMS-626529
Study: NCT02322320
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.
Study: NCT02388061
Drug: Tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02388061
Drug: Tissue Plasminogen Activator
Normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01996735
Drug: Ticagrelor 180 mg single dose
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00466999
Drug: misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of 400 mcg misoprostol administered sublingually
Study: NCT01996202
Drug: Ipilumimab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04023695
Drug: Corticosteroid with normal saline
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger finger injection
Study: NCT02216331
Drug: rifapentine
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02216331
Drug: rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03448718
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 cycle = 28 days. Subject's with calculated creatinine clearance (CrCl) of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of \> 30 to \< 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.
Study: NCT03870711
Drug: lidocaine spray
Normalized name: lidocaine Mucosal Spray
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10% lidocaine spray 4 puffs
Study: NCT01477190
Drug: Patient Control Analgesia (PCA) Morphine
Normalized name: lauryl PCA
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
Study: NCT01073696
Drug: granisetron IV
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT01073696
Drug: granisetron patch
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patch
Study: NCT00710034
Drug: Nicotine Gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg Nicotine gum
Study: NCT00392171
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive temozolomide 50 mg/m\^2 for cycles of 28 days for 12 months or until progression
Study: NCT02392039
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.
Study: NCT02392039
Drug: Loratadine
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 1 - Cycles 1 and 3: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 2 and 4: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.
Study: NCT02340819
Drug: Teduglutide
Normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
Study: NCT00313807
Drug: Amino Acid
Normalized name: Amino Acid
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% amino acid infusion
Study: NCT02988466
Drug: GVHD Prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Cyclophosphamide (Cy)~* Tacrolimus (Tac)~* Mycophenolate mofetil (MMF)
Study: NCT01589068
Drug: Intravenous Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70 kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
Study: NCT01589068
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
Study: NCT03648281
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Study: NCT00414310
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m\^2 IV over 1 hour daily for 5 days.
Study: NCT00414310
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/kg orally daily for 7 days
Study: NCT04008433
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Advanced intravenous injection of lidocaine before the propofol injection
Study: NCT00074100
Drug: amonafide dihydrochloride
Normalized name: amonafide
DrugBank: Amonafide (DB05022)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02391480
Drug: ABBV-075
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-075 Oral tablets
Study: NCT02391480
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax tablets, film-coated
Study: NCT00660036
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: On Day 6 of an inpatient hospital stay: Based on the study design patients will be treated with one of three doses (3 mg/m\^2, 6 mg/m\^2 or 9 mg/m\^2), administered intravenously in 100 ml of 0.9% sodium chloride over 2 hours.
Study: NCT00660036
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Days 1-3 of an inpatient hospital stay: 10 mg/m\^2 administered via IVPB (intravenous piggy-back) in 50ml normal saline (NS) over 15 minutes
Study: NCT00660036
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On Days 1-5 of an inpatient hospital stay: 100 mg/m\^2 administered intravenously in 500 ml of 0.9% sodium chloride over 2 hours
Study: NCT00683956
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00151060
Drug: Estramustine
Normalized name: Estramustine
DrugBank: Estramustine (DB01196)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00151060
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00151060
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01830361
Drug: midostaurin (PKC412)
DrugBank: Midostaurin (DB06595)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Midostaurin 50 mg (2 capsules) twice daily days 8-21 in induction II + consolidation I-III; maintenance treatment twice daily continuously for 12 months
Study: NCT02436577
Drug: Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water
Normalized name: Ticagrelor Tablets
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 90 mg OD tablet, single dose
Study: NCT02436577
Drug: Ticagrelor OD tablet (90 mg single dose) administered without water
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 90 mg OD tablet, single dose
Study: NCT02436577
Drug: Ticagrelor IR tablet (90 mg) administered with 150 mL of water
Normalized name: Ticagrelor Tablets
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 90 mg IR tablet, single dose
Study: NCT01598857
Drug: Blisibimod
Normalized name: Blisibimod
DrugBank: Blisibimod (DB12330)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03333057
Drug: NOV03
Normalized name: NOV03
DrugBank: Perfluorohexyloctane (DB17823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfluorohexyloctane
Study: NCT00137852
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given weekly on weeks 1, 2, 4 and 5 during radiation therapy.
Study: NCT00137852
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given weekly on weeks 1, 2, 4 and 5 during radiation therapy
Study: NCT03158688
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Commercially available oral and IV formulas were obtained by investigative sites. Amgen supplied IV or PO dexa for some countries (Poland, Hungry, Romania, Bulgaria, Korea). Dosage modification rules applied based on participant age (participants \> 75 years were given lower doses), dexa-related toxicities, and discontinuation of carfilzomib.
Study: NCT03158688
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab was supplied as a concentrated solution for infusion in single-use vials.
Study: NCT03158688
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carfilzomib for infusion was supplied as a lyophilized, sterile product in single-use vials. The lyophilized product was reconstituted with preservative-free sterile water for injection, the reconstituted solution contained carfilzomib 2 mg/mL. IV injections lasted approximately 30 minutes.~Dose could be modified based on a \>20% change in body weight or toxicity.
Study: NCT02220348
Drug: linaclotide
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01152333
Drug: Exendin-(9-39) Acetate
Normalized name: Exendin 4
DrugBank: Avexitide (DB14806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exendin (9-39) will be diluted in saline 0.9% and administered through IV infusion once for a maximum of 2.5 hours in length.
Study: NCT02037802
Drug: Pethidine
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
Study: NCT02037802
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fentanyl propofol atracurium besylate
Study: NCT02037802
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02979886
Drug: GnRH-a
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the hormone reaction to the down regulation of the patients
Study: NCT02979886
Drug: Human Menopausal Gonadotropins
Normalized name: Human menopausal gonadotropin (urine derived)
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the effects on the serum LH level of day of HCG
Study: NCT02849990
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02849990
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02849990
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given SC
Study: NCT02849990
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04397406
Drug: levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients will receive 15 ml of 0.125% levobupivacaine.